Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2
Patients on insulin or sulfonylureas should consider MOTS-c a glucose-modifying agent until formal interaction data exist
How does FOXO4-DRI differ from other senolytics like dasatinib + quercetin
Most compounds in the fat-loss space work through one of two levers: appetite suppression or increased energy expenditure
Additionally, regulatory frameworks in several regions are evolving to support remote and virtual trial models, helping reduce logistical challenges and expanding patient access to clinical research
US$ 26.56
US$ 21.29
US$ 21.12
US$ 26.09
US$ 29.41
US$ 21.08
US$ 23.20
